Why the study?
What are the plasma concentrations and interpatient variability of verapamil and norverapamil during long-term therapy in patients with hypertrophic obstructive cardiomyopathy?
Population
31 patients with hypertrophic obstructive cardiomyopathy
Design
Cohort
Follow-up
6 months to 5 years
Authors
Loading...
Marked 25-fold variability in verapamil levels may support TDM consideration in HOCM; leaves open outcome impact of monitoring.
What are the plasma concentrations and interpatient variability of verapamil and norverapamil during long-term therapy in patients with hypertrophic obstructive cardiomyopathy?
Long-term verapamil therapy in hypertrophic obstructive cardiomyopathy patients exhibits massive interpatient variability in plasma concentrations, suggesting therapeutic drug monitoring may be necessary to guide dosing.
Woodcock et al. (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: